OpenAI Releases GPT-Rosalind for Biological Research
New frontier model aims to accelerate drug discovery and complex protein engineering for the life sciences.
A digital lab interface showing a complex 3D protein model and chemical synthesis data in a modern research setting.
Photo: Kronos News
OpenAI launched GPT-Rosalind on Sept. 22, 2026, marking its first frontier model dedicated to biological research and drug discovery [1]. Named after scientist Rosalind Franklin, the model is optimized for translational medicine and complex multi-step tasks [1][2]. It specifically focuses on organic chemistry synthesis and protein engineering [1].
The system aims to compress the traditional 15-year drug discovery timeline significantly [1]. Industry experts suggest that AI is now essential in biopharma to manage research evidence [3]. By improving evidence handling, OpenAI expects GPT-Rosalind to assist scientists in identifying novel therapeutic leads more efficiently [1][2].
Editorial notes
Transparency note
AI assisted drafting. Human edited and reviewed.
- AI assisted
- Yes
- Human review
- Yes
- Last updated
Risk assessment
Reviewed for sourcing quality and editorial consistency.
Sources
Related stories
View all
About the author
Kronos News Desk covers news and editorial analysis for Kronos News.